Introduction
The endodermally derived pancreas consists of both exocrine and endocrine compartments. The exocrine tissue is composed of acinar and duct cells and functions in the synthesis and secretion of digestive enzymes. The endocrine pancreas controls blood glucose homeostasis and is comprised of the islets of Langerhans, which in the adult murine pancreas contain insulin-secreting b-cells, glucagon-secreting a-cells, somatostatin-secreting d-cells, and pancreatic polypeptide-secreting PP cells. Endocrine cell development requires expression of the basic helix-loop-helix (bHLH) transcription factor Neurogenin3 (Ngn3). Deletion of Ngn3 abolishes differentiation of all pancreatic endocrine cells (Gradwohl et al., 2000; Lee et al., 2002a) , and lineage-tracing experiments have shown that all mature endocrine cells are derived from Ngn3-positive precursors (Gu et al., 2002) . (Apelqvist et al., 1999) . Notch, a plasma membrane receptor, is proteolytically cleaved upon binding of its ligands (Selkoe and Kopan, 2003) , which in the murine pancreas are Delta-like1 (Dll1), Jagged1 (Jag1) and Jagged2 (Jag2) (Apelqvist et al., 1999; Jensen et al., 2000) . Cleaved Notch translocates into the nucleus where it binds to and activates the transcription factor RBP-Jj (Kramer, 2001; Mumm and Kopan, 2000) . RBP-Jj upregulates the Hes and Hey (also known as Hrt or Herp) families of repressors, which in the pancreas bind to the Ngn3 promoter and inhibit its transcription (Bertrand et al., 2002; Iso et al., 2003; Kageyama and Ohtsuka, 1999) . When the Notch signaling components Rbpj, Dll1, or Hes1 are deleted, Ngn3 expression in the pancreas increases, and pancreatic precursor cells differentiate prematurely into endocrine cells. This depletes the pool of progenitors and leads to decreased exocrine and endocrine mass and usually an increase in the endocrine/exocrine ratio (Apelqvist et al., 1999; Fujikura et al., 2006; Jensen et al., 2000) .
In addition to the core signaling components, additional proteins modulate the activity of the Notch pathway, including the Fringe family of glycosyltransferases. Fringe molecules glycosylate Notch, thereby modifying the receptor's response to its ligands (Haltiwanger and Stanley, 2002; Moloney et al., 2000; Panin et al., 2002) . In Drosophila, Fringe limits the domain of Notch activation during wing and epidermis development (Klein and Arias, 1998; Walters et al., 2005) . In general, glycosylation increases the response of Notch to Delta-like, but decreases Jagged-induced Notch signaling. In mammals, this decrease in Jagged-induced Notch cleavage occurs with no reduction in Jagged-Notch binding (Hicks et al., 2000; Yang et al., 2005) . Of the three mammalian Fringe proteins (Lunatic, Radical, and Manic), only Manic Fringe (Mfng) expression can be detected up to E14.5, and then Lunatic Fringe (Lfng) is expressed only in differentiated acinar tissue (Svensson et al., 2009; Xu et al., 2006) . Mfng expression partially overlaps with Ngn3 expression in the developing murine pancreas (Svensson et al., 2009; Xu et al., 2006) , and overexpression of Mfng induces Ngn3 expression in chick endoderm, presumably by inhibiting Notch signaling (Xu et al., 2006) . Notch signaling can function at several stages during the differentiation of a single organ and can play multiple roles within a given tissue. For example, Notch signaling acts at several steps in hematopoiesis, myogenesis, and neurogenesis (Cagan and Ready, 1989; Fuerstenberg and Giniger, 1998; Hartenstein, 2006; Hirsinger et al., 2001) . Additionally, during immune cell differentiation, various Notch components can possess non-redundant roles in the same tissue. For example, Notch1 is required to specify the T-vs. B-cell lineage, while Notch2 controls further differentiation into the various types of B-cells (Hartenstein, 2006) . In the zebrafish, deltaA deficient mutants lack a-cells, jagged1b deficient embryos have an increase in a-cells, and jagged2 deficient embryos have an increased percentage of endocrine cells within the pancreas, indicating that different ligands have different roles in zebrafish pancreas development (Zecchin et al., 2007) . In the murine pancreatic bud, Dll1 is expressed at E9.0, but Jag1 is not expressed until later (Apelqvist et al., 1999) . Since various Notch ligands have different spatiotemporal expression patterns within the pancreatic anlage, they may also have diverse functions during mammalian pancreatic development.
The roles of the Notch ligands in mammalian pancreatic development have not been thoroughly studied due to the early embryonic lethality of Dll1 À/À and Jag1 À/À mice (Hrabe de Angelis et al., 1997; Xue et al., 1999) . Here, we show that Jag1 is the most abundant Notch ligand during mid-gestation pancreatic development. To delineate the role of Jag1 during pancreatogenesis, we use the Cre-loxP system to delete the gene in the foregut endoderm, from which the pancreas is derived. We demonstrate that although the postnatal phenotype is similar to the embryonic phenotype of other Notch signaling mutants, the embryonic phenotype is strikingly different. Surprisingly, in the fetal pancreas, the endocrine and pro-endocrine cell percentage is reduced in Jag1 mutants while direct transcriptional targets of Notch are upregulated, mimicking Notch activation. We show further that Jag1 can act as a competitive inhibitor of Dll ligands in vitro when Notch is modified by Mfng glycosylation, providing a molecular model possibly explaining the upregulation of Notch targets observed in the Jag1-defecient fetal pancreas.
Results

Expression analysis Notch ligands in the developing pancreas
We analyzed the mRNA levels of Notch ligands to determine which of them is most abundant during pancreatogenesis. We developed primers for Dll1, Jag1, and Jag2 that amplified their targets with equal efficiency, allowing for a quantitative comparison of mRNA levels for the three genes (Fig. 1A) . mRNA for all three ligands could be detected as early as E12.5 and throughout second wave endocrine cell development, the period during which most pancreatic endocrine cells differentiate. Jag1 mRNA expression was consistently higher than that of the other two ligands (Fig. 1B) ; we cannot, however, exclude the possibility that the relative abundance of the three ligand protein levels varies due to differences in mRNA translatability or protein stability.
Next we analyzed the localization of Jag1 protein in the developing epithelial pancreas. At E12.5, Jag1 protein was present in every cell positive for the epithelial pancreatic precursor marker Pdx1 (Fig. 1C-F) . Co-expression of Jag1 and Pdx1 was also observed throughout the E14.5 pancreatic epithelium (data not shown). At E14.5, Jag1 protein was also present in differentiated endocrine cells, demonstrated by co-staining with glucagon, the most abundant endocrine marker at this timepoint ( Fig. 1G-J) . At E16.5, Jag1 protein was detectable in some but not all cells positive for markers of differentiated pancreatic cell types-glucagon, insulin, and somatostatin, and for the exocrine marker amylase (data not shown). By E18.5, Jag1 was limited to duct and endocrine cells (Fig. 1K-R) . Peri-and postnatally, epithelial Jag1 is limited to the pancreatic ducts (Golson et al., 2009 ). Due to the widespread and abundant expression of Jag1 throughout the early pancreatic epithelium, we evaluated the consequences of deleting Jag1 in the developing pancreas. Fig. 1 -Jagged1 is initially expressed throughout the pancreatic epithelium but gradually becomes limited to ducts. (A) Primers for Jag1, Jag2, Dll1 and TBP amplify with equal efficiency. Not all of icons can be seen because they lie on top of each other. (B) qRT-PCR on total pancreas RNA for Jag1, Jag2 and Dll1 (normalized to TBP) indicate that Jag1 is expressed at much higher levels than the other Notch ligands throughout pancreas development (n = 4). (C-R) Indirect immunofluorescence, shown both as single channel images of Pdx1, glucagon, DBA lectin, or insulin (column 1) plus Jag1 (column 2), the nuclear marker DAPI (column three) and merged images (column 4). (C-F) At E12.5, immunostaining indicates that Jag1 (D) is expressed in all Pdx1-expressing cells (C), which mark the undifferentiated pancreatic epithelium. (G-J) Jag1 (H) is expressed in differentiated a-cells (glucagon expression, G) at E14.5, the predominant endocrine cell at this timepoint. (K-N) At E18.5, Jag1 (L) is expressed in ducts labeled with DBA lectin (K). (O-R) Jag1 (P) is also expressed in differentiated islets at E18.5 (insulin, O). For all images, bar = 25 lm except insets, where bar = 50 lm.
Since early embryonic lethality of Jag1 À/À mice has precluded analysis of the role of Jag1 in pancreatic development thus far (Mitsiadis et al., 1997) (Gu et al., 2002; Lee et al., 2005; Loomes et al., 2007) . Because Foxa3-Cre is expressed in the foregut endoderm beginning at E8.5, Jag1 was deleted in the epithelium of several derivative organs, including the pancreas, liver, and stomach , while Pdx1-Cre deletes throughout the epithelium of the pancreas only, beginning at E9.0 (Gu et al., 2002; Heiser et al., 2006 ;Foxa3-Cre mice, excluding those with pancreatitis or fatty infiltration of the pancreas.
Quantitative RT-PCR analysis of Jag1 mRNA in embryonic and postnatal pancreas with primers specific to exons 4 and 5 indicated a reduction of 50-65% in Jag1 message beginning at E15.5 and continuing through postnatal development ( Fig. 2A) , with a similar reduction at the protein level (Fig. 2B) . Thus, the extent of Jag1 deletion remains constant throughout fetal development and postnatal life of the mutants, suggesting that Jag1 deficient epithelial cells are not at a competitive disadvantage in this model. Remaining Jag1 is probably in endothelial cells, where Foxa3-Cre is not expressed, indicating that about half of the Jag1 mRNA observed in wildtype animals is from endothelial cells. Despite the activation of Foxa3-Cre at E8.5, significant deletion of Jag1 occurs later in this model than in Jag1 loxP/loxP ;Pdx1-Cre early mice, in which Jag1 mRNA was reduced to 54% of control levels by E14.5 (p = 0.017; Supplementary Fig. 1 ). Immunostaining indicates that by E18.5, no Jag1 expression remains in epithelial cells ( Fig. 2C-J 
a-cell mass is altered postnatally in Jag1 mutants
Based on the phenotype of other Notch pathway mutants, endocrine cell lineage allocation in postnatal mutant animals ;Foxa3-Cre + animals no longer display Jag1 in E-cadherin-expressing islet clusters.
was examined using several cell-type specific markers. Using immunostaining, we found an approximate 2.5-fold increase in a-cell mass in P21 Jag1 mutants vs. controls (131 ± 36 vs. 48 ± 13 lg), with no change in b-cell (194 ± 62 vs. 200 ± 59 lg), d-cell (23 ± 14 vs. 17 ± 4 lg), or PP-cell mass (9 ± 4 vs. 7 ± 1 lg) ( Fig. 3A -G). The expected increase in total endocrine mass did not reach significance (Fig. 3G ). Expression levels of endocrine genes were examined to confirm our histological findings. As expected, mRNA levels of several a-cell-specific genes were increased significantly at P12-pre-proglucaon by $70%, the pro-a-cell transcription factor Arx by $80%, and the a-cell specific transcription factor Brn4 by $100% (Fig. 3H) (Collombat et al., 2005 (Collombat et al., , 2007 (Collombat et al., , 2003 Heller et al., 2004) . In concordance with an unchanged b-cell mass, no difference was detected in insulin mRNA at P12 (Fig. 3H) , in fed or fasted blood glucose or in glucose tolerance at P20-21 (data not shown).
2.3.
Ngn3 is upregulated in postnatal Jag1 mutants
We examined Ngn3-positive cells at P0 and observed just a few cells that were Ngn3
+ in controls as expected since Ngn3 is dramatically downregulated around birth ( Fig. 4A ) but many that were positive in mutants ( Fig. 4B ). We also investigated Ngn3 expression by utilizing a Ngn3-eGFP ''knock-in'' allele (Lee et al., 2002a) . P7 pancreata from both Jag1 (Fig. 4C ). In contrast, mutant pancreata contained large numbers of eGFP-expressing cells, indicating persistent Ngn3 gene activation (Fig. 4D) . The abnormal postnatal expression of Ngn3 partially explains the Jag1 mutant phenotype described above, i.e. the increased percentage of endocrine cells within the pancreas and the increased percentage of a-cells within the endocrine compartment.
Exocrine mass is reduced in postnatal Jag1 mutants
Since other Notch mutants have reduced pancreas weight due to precocious endocrine differentiation and loss of pancreatic precursors, we examined the pancreas weight of Jag1 mutants. At P21, total pancreas weight was reduced in Jag1 mutants postnatally (Fig. 5A ). This reduction in weight can be attributed to loss of exocrine mass since approximately 95% of pancreas weight in wildtype animals is exocrine tissue. Note that this reduction in pancreas size indicates that endocrine percentage in Jag1 mutants is increased compared to controls (0.89 ± 0.25 vs. 0.43 ± 0.11% of total pancreas mass), since endocrine mass is maintained in Jag1 mutants. Because Jag1 was not deleted significantly until E15.5, we examined embryonic pancreatic area to determine when the onset of decreased pancreatic size occurred and detected no difference at E12.5, E16.5, or E18.5 (Fig. 5B) . We thus inferred that decreased exocrine mass in the Jag1 mutants did not result from a depletion of general pancreatic progenitors and therefore examined acinar cell death using TUNEL staining. At P0-P1, the number of TUNEL-positive acinar cells was increased in Jag1 mutants ( Fig. 5C-E) , indicating that the decrease in exocrine tissue was due to exocrine cell death, not a change in lineage allocation. This increase in acinar cell death is reduced compared to that in Jag1 loxP/loxP ;Pdx1-Cre early mice, and fibrosis was never observed at P0 or P14 in Jag1 loxP/loxP ;Foxa3-Cre animals.
Embryonic phenotype mimics Notch activation
Since the size of the mutant embryonic pancreas was not decreased, we suspected that the Jag1-deficient embryonic pancreas may have unexpected differences compared to other Notch signaling mutants. We examined embryonic pancreata at E12.5 and E14.5, but detected no significant differences between controls and mutants. We then examined E16.5 embryonic pancreata. Unlike Dll1 and Hes1 null embryos and pancreas-specific Rbpj mutants, Ngn3, glucagon, and insulin mRNA were significantly downregulated in total pancreas at E16.5 while the Notch targets Hes5 and Hey1 were significantly upregulated, indicating an increase in Notch signaling despite ablation of the most abundant Notch ligand from the pancreatic epithelium (Fig. 6A) . No difference was detected in amylase mRNA levels (Fig. 6A) . Ngn3
+ , a-and b-cell numbers were quantified, showing that the number of endocrine precursors and glucagon-positive cells was reduced by approximately one-half at E16.5 (Fig. 6B-G) . Insulin-positive cell numbers were the same in controls and mutants, suggesting that the reduction in insulin mRNA resulted from reduced transcription rather than a reduced cell number, possibly indicating immaturity of the bcells. We examined Jag2 and Dll1 levels to determine whether upregulation of these two ligands could account for the increase in Notch signaling at E16.5, but no significant increase was observed (Supplemental Fig. 2 ). Jag1 loxP/loxP ;Pdx1-Cre early mice also exhibited reduced levels of Ngn3, glucagon, and insulin mRNA at E16.5 but at E14.5 only Ngn3 mRNA was reduced, indicating that the earlier deletion in the Jag1 loxP/loxP ;Pdx1-Cre early mice does not change the timing of the decrease in endocrine cells (Supplementary Fig. 3 ).
To address when Jag1 mutant endocrine cell numbers begin to catch up to those of control mice, we examined ngn3, ins, and glu mRNA at E18.5. All three genes were expressed at the same level in control and Jag1 mutant pancreas at this stage (Fig. 6H) . To confirm this finding, we also quantified the number of a-and b-cells and found no difference, indicating that Jag1 mutant embryos begin to recover from the increased Notch signaling observed at E16.5 by E18.5 (Fig. 6I) . To determine the mechanism of recovery of the Ngn3-and glucagon-positive cells, we examined the percentage of these cells that had entered or passed through S-phase using BrdU. No difference was apparent at E16.5 or E18.5 in BrdU-positive a-or b-cells (Fig. 6J) , and there were very few BrdU-positive Ngn3-positive cells in either mutants or controls (data not shown), indicating that the increase in endocrine precursors and in a-cells after E16.5 is the result of de novo generation of these cell populations or a perdurance of pre-existing Ngn3-positive cells. We hypothesized that the paradoxical phenotype observed in the fetal Jag1 loxP/loxP ;Foxa3-Cre + pancreas might result from modifications of the Notch signaling pathway. In mammals, Fringe glycosyltransferases decrease the Jagged-Notch signal without affecting binding of Jagged and Notch. Mfng is expressed in some Ngn3 + cells, and it induces Ngn3 expression in undifferentiated chick endoderm (Svensson et al., 2009; Xu et al., 2006) , the same phenotype as a decrease in Notch signaling effected by a Rbpj, Hes1, or Dll1 knockout (Apelqvist et al., 1999; Fujikura et al., 2006; Jensen et al., 2000) . We postulated that Mfng may be acting within the endocrine precursor lineage as a modifier of Notch signaling by causing Jag1 to act as a competitive inhibitor of Dll1 signaling. We therefore examined Mfng expression in endocrine progenitors, sorted on the basis of Ngn3-eGFP expression. Cells positive for eGFP expression (i.e. endocrine precursors and early endocrine descendents) expressed Mfng at levels that were between 10-and 20-fold greater than those of eGFP À cells at all time points examined; Mfng expression was extinguished in mature islets (Fig. 7A ).
To further test our hypothesis that Jag1 is acting as a Notch inhibitor in the presence of Mfng expression, we examined Notch cleavage in cells containing either a control plasmid (3T3E) or a Mfng-expressing plasmid (3T3M). We plated these cells on Jag1 ligand alone, Dll1 ligand alone, or a combination of both ligands. Jag1 and Dll1 alone as well as in combination with each other induced Notch activation in control cells (Fig. 7B, lanes 3, 5 and 7) . Mfng expression reduced Notch1 activation in cells plated on Jag1 ligand slightly, confirming previous results (lanes 3 and 4; (Hicks et al., 2000; Klein and Arias, 1998; Moloney et al., 2000; Yang et al., 2005) ). Notch activation was unchanged in cells plated on Dll1 (Fig. 7B, lanes 5 and 6) , which was not very surprising since Mfng potentiates Dll1 signal through Notch1 less than Rfng or Lfng in 3T3 cells (Yang et al., 2005) . 3T3M cells plated on a combination of Jag1 and Dll1 ligands showed low levels of cleaved Notch compared to cells plated on Dll1 alone, indicating that Jag1 can act as a competitive inhibitor of Dll1 in the presence of Mfng expression (Fig. 7B , compare lanes 7 and 8 to lanes 5 and 6). These data support a model in which Jag1 and Mfng induce the expression of Ngn3 by suppressing Dll1-Notch signaling (Fig. 7C) .
Discussion
The robust expression of Jag1 in the embryonic pancreas suggested that this gene plays a major role in pancreatogenesis. Of course, translational efficiency of the various Notch ligands differ, so although mRNA levels of Jag1 are higher than those of Dll1 and Jag2, protein levels may not exactly reflect mRNA levels. Deletion of Jag1 in the foregut endoderm, which gives rise to the pancreatic epithelium, leads to a postnatal phenotype similar to early embryonic phenotypes of Hes1 and Rbpj mutants (Fujikura et al., 2006; Jensen et al., 2000) . This similarity may be surprising since a recent report detailing a compound knockout of Notch1/2 describes a very mild pancreatic phenotype compared to those of Hes1 and Rbpj mutants; these Notch1/2 double knockout mice did not have any dysregulation of Ngn3. The mild phenotype observed in the Notch1/2 compound mutant may, however, be due to expression of Notch3/4 in the pancreatic epithelium. Although one group has reported that only Notch1/2 are expressed in the pancreatic epithelium (Lammert et al., 2000) , others have demonstrated epithelial expression of Notch3/4 as well (Apelqvist et al., 1999) . Jag1 loxP/loxP ;Foxa3-Cre + mice display important differences in comparison with previously reported Notch pathway mutants. Jag1-deficient pancreata have normal total endocrine mass and a full complement of b-cells while other Notch signaling mutants have reduced endocrine mass despite an increased percentage of endocrine cells (Apelqvist et al., 1999; Fujikura et al., 2006; Jensen et al., 2000) . Jag1 mutants also have a reduced Ngn3 + population at E16.5 but have persistent Ngn3 expression after birth, while the pancreas-specific Rbpj mutant has an increased Ngn3 + population at E10.5 but reduced thereafter (Fujikura et al., 2006) . Finally, Jag1 mutants have decreased exocrine mass due to acinar cell death, not due to a change in cell lineage allocation with precocious differentiation of common pancreatic progenitors. This increase in acinar cell death may indicate that Notch signaling promotes acinar cell survival; Jag1 loxP/loxP ;Pdx1-Cre early mice also exhibit acinar cell death, at even higher rates than Jag1 loxP/loxP ;Foxa3-Cre + mice, with fatty replacement of the acinar tissue; the acinar cell death is probably due to ductal malformation (Golson et al., 2009 ). The acinar cell death in Jag1 loxP/loxP ;Foxa3-Cre + mice may also result from a ductal malformation that could be less severe due to the later deletion Jag1 loxP/loxP ;Foxa3-Cre + mice.
Like many other Notch signaling pathway mutants, Jag1 mutants have an increased percentage of a-cells within the endocrine compartment. However, due to the timing of increased Ngn3 expression, the increase in a-cells is unexpected since the competency of the fetal pancreas to produce a-cells because of Ngn3 overexpression decreases dramatically with age (Johansson et al., 2007) . Differences observed in these two models could be explained in at least two ways: (1) misexpression of Ngn3 under control of the Pdx1-Cre promoter initially causes it to be expressed in pancreatic progenitor but later in b-and d-cells, and this misexpression leads to the change in percent of differentiating a-cells; or (2) embryonic Notch upregulation in the Jag1 mutant pancreatic epithelium leads to competency alterations due to persistent general pancreatic precursors, such as in mice that overexpress Notch1 (Hald et al., 2003) . Differentiated cells of all types, including acinar, islet, and duct cells are observed in neonates, however, and no markers of general pancreatic precursors are available that do not also mark differentiated cell types; therefore, determining whether more pancreatic -6) , or a combination of both (lanes 7-8) and Notch activation was measured by immunoblotting for cleaved Notch1. All ligands activated Notch cleavage compared to uninduced cells (lanes 1 and 2) , and the combination of Dll1, Jag1, and Mfng yielded low levels of Notch activation ( * p < 0.05). (C) Model: Manic Fringe promotes endocrine differentiation by causing Jag1 to act as a competitive inhibitor of Dll1 during pancreatogenesis. When Mfng expression is high, resulting in high levels of Notch glycosylation, Jag1 binds to but does not activate Notch, thus acting as a competitive inhibitor of Dll1. In this situation, Notch signaling decreases, Hes/Hey gene expression decreases, and Ngn3 is expressed. However, in Jag1 mutants, Dll1 has increased access to the Notch receptor, and glycosylation potentiates the cleavage of Notch when bound by Dll1, leading to relatively high Notch activation in cells that express Mfng. Active Notch signaling represses Ngn3 expression, resulting in fewer endocrine precursors and differentiated endocrine cells.
progenitors are present in the late embryonic and perinatal Jag1 mutant pancreas has proven difficult.
Our most surprising finding is that during fetal life, Jag1 mutants mimic an increase in Notch signaling rather than the expected decrease. E16.5 Jag1 mutants have a reduced endocrine population, while direct transcriptional targets of Notch-Hes5 and Hey1-are upregulated, and Ngn3 expression is decreased compared to control littermates. This striking phenotype may be explained by the spatially and temporally restricted presence of the Notch glycosyltransferase, Mfng, which is expressed highly in endocrine progenitors but is absent or very low in the rest of the embryonic pancreas or in differentiated pancreatic cells. Mfng has previously been reported to induce endocrine cell development when overexpressed in chick endoderm and to overlap partially with Ngn3 in the developing murine pancreas (Svensson et al., 2009; Xu et al., 2006) .
A recent report suggests that Mfng is unnecessary for pancreas development (Svensson et al., 2009) . Mfng null mice displayed no change in endocrine cell number or ratio between E9.5 and E14.5, and adults had normal pancreas morphology with no defects in blood glucose homeostasis. Endocrine cell counts after E14.5 were not reported, however, and endocrine cell number defects were not observed in Jag1 mutants until after E14.5. Therefore, this recent report does not preclude the possibility that Mfng causes Jag1 to act as an inhibitor of Notch signaling in the embryonic pancreas.
Genetic evidence in Drosophila supports the hypothesis that Jag1 can act as an inhibitor of Notch signaling in the presence of Fringe (de Celis et al., 1998; Klein and Arias, 1998 (Hicks et al., 2000; Yang et al., 2005) . In addition to the reduced signaling efficacy from Jag1 in the presence of Mfng, we show that Jag1 can act as a competitive inhibitor of Dll1-induced Notch signaling when Mfng is expressed (Fig. 7B) .
We present a model in which Jag1 binds to but does not activate glycosylated Notch and interferes with Dll1 binding, leading to relatively low levels of Notch activation (Fig. 7C) . Since endocrine precursors express high levels of Mfng, and genetic ablation of Jag1 leads to increased rather than decreased Notch signaling as assayed by Hes5, Hey1, and Ngn3 expression at E16.5, the function of Jag1 during pancreatogenesis may be to limit the number of cells with activated Notch, just like Serrate in the Drosophila wing margin. Increased Notch signaling observed in Jag1-deficient pancreata may be the result of more efficient binding between Dll1 and Notch receptors, leading to high levels of Notch activation and thus reduced Ngn3 expression.
Many modifiers of the Notch signaling pathway exist and our experiments do not unequivocally determine that Mfng is the reason that Jag1 mutants display increased Notch activation in the embryonic pancreas. However, we do show that Jag1 can act as an inhibitor of Dll1-induced Notch activation when Notch is glycosylated and that Mfng is highly expressed in endocrine progenitors. Our experiments also indicate that Jag1 normally inhibits Notch signaling embryonically but can stimulate it postnatally. In summary, we have shown that different Notch ligands have non-redundant roles in the developing pancreas and each serves to fine-tune the process of endocrine and exocrine cell differentiation from common precursors.
4.
Experimental procedures
Animals and genotype analysis
The derivation of Jagged1 loxP , Ngn3-eGFP, and Foxa3-Cre mice has been reported previously (Gu et al., 2002; Lee et al., 2005 Lee et al., , 2002a Loomes et al., 2007; Soriano, 1999) . All mice were maintained on a C57Bl/6J;129/SvEv background. Genotyping was performed by PCR analysis using genomic DNA isolated from the toe tips of newborn mice. Littermate Jag1 loxP/loxP and Jag1 loxP/+ mice were used as controls in most experiments. All procedures involving mice were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania.
Tissue culture
NIH 3T3 cells were transfected with human Mfng cDNA in a pCMV-XL4 plasmid or with pCMV-XL4 control plasmid (OriGene, Rockville, MD, USA) along with a neomycin-resistance containing vector (PL452) at a 5:1 (PL452) using Fugene6 (Roche, Nutley, NJ, USA) and positive cells were selected using 750 lg/ ml Geneticin. Mfng expression was confirmed by RT-PCR. HEK 293 cells were transiently transfected with Jag1-Fc or Dll1-Fc expression vectors (gifts from Drs. Tom Kadesch and Joseph Verdi) using Lipofectamine 2000 (Invitrogen), and conditioned media was collected. 10 cm plates were sequentially incubated for one hour at room temperature with 10 lg/mL anti-Fc antibody (Jackson) in sterile 1· PBS and then conditioned media containing Jag1-Fc, Dll1-Fc or a 1:1 combination of the two ligands. Mfng-expressing or control cells were plated and whole cell extracts (WCE) were collected 24 h later and assessed for cleaved Notch1 by immunoblotting. For quantification, QuantiOne software (Bio-Rad; Hercules, CA, USA) was used. Blots were normalized to the ratio between cleaved Notch1 and a-tubulin in Jag1-Fc induced 3T3 cells.
Immunoblotting (IB) and immunostaining
The following antibodies were used: goat anti-Jag1 (C-20, 1:200; Immunoblot; Santa Cruz Biotechnologies, Santa Cruz, CA, USA), rabbit anti-Jag1 (28H8, 1:200-500; immunostaining; Cell Signaling Technology, Danvers, MA, USA), goat antiPdx1 (A17, 1:200; Santa Cruz), mouse anti-Ngn3 (F25A1B3, 1:1000; Hybridoma Bank, Iowa City, Iowa) guinea pig antiinsulin (1:800; Linco Research Inc., St. Charles, MI, USA), rabbit anti-glucagon (undiluted; Zymed Laboratories Inc., South San Francisco, CA, USA), guinea pig anti-glucagon (1:3000-5000; Linco), goat anti-glucagon (1:200; Santa Cruz) goat anti-somatostatin (1:5000; Santa Cruz), rabbit anti-pancreatic polypeptide (1:50; Zymed), rabbit anti-Chromogranin A (1:1500; DiaSorin, Stillwater, MN, USA), goat anti-amylase (1:200; Santa Cruz), rat anti-CK19 (1:50, TromaIII, Hybridoma Bank), sheep anti-BrdU (1:1000; US Biologicals, Swammscott, MA, USA), rabbit anti-cleaved Notch1 (1:1000; Abcam), mouse anti-acetylated a-tubulin (1:5000; Sigma, St. Louis, MO, USA), Cy3-conjugated donkey anti-rabbit IgG (1:600; Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA), Cy2-conjugated donkey anti-rabbit IgG (1:400; Jackson), Cy3-conjugated donkey anti-sheep (1:600; Jackson), Cy2-conjugated donkey anti-guinea pig IgG (1:600; Jackson) and Cy2-conjugated donkey anti-goat IgG (1:600; Jackson), biotinylated anti-rabbit IgG (1:200; Vector Laboratories, Burlingame, CA, USA), biotinylated anti rat-IgG (1:200; Vector), HRP-conjugated anti-rabbit IgG (1:10,000; Jackson; IB), HRP-conjugated anti-mouse IgG (1:2000; IB; Jackson) and HRP-conjugated anti-goat IgG (1:2000; Jackson; IB).
Indirect immunofluorescence was performed as previously described on paraffin-embedded tissue (Sund et al., 2001 ) and examined using epifluorescent microscopy (Nikon Eclipse E600 microscope; Cool Snap CF camera). Immunohistochemistry was performed as previously described (Gupta et al., 2005) . DBA staining was performed according to manufacturer's instructions (Vector).
For determination of postnatal endocrine cell mass, pancreata were laid flat during the paraffin-embedding process and cut for maximal footprint. Quantification of endocrine cell mass was performed by immunostaining against Chromogranin A and counterstaining with hematoxylin (Zymed). The entire pancreas of each animal was imaged at 60· and the area of both exocrine and endocrine compartment was analyzed using Metamorph software (Molecular Devices, Downingtown, PA, USA). The percentage of area occupied by endocrine cells was then multiplied by pancreas mass to determine endocrine cell mass. For individual cell types, slides were labeled with antibodies against insulin and glucagon, against insulin and somatostatin, or against insulin and pancreatic polypeptide. Images of the first 10-20 islets encountered per mouse were taken at 240·. IPLab software was used to quantify the area positive for each hormone per slide in square microns (BD Biosciences, Rockville, MD, USA). Total microns for each hormone per mouse were added together and the insulin-positive area per mouse was averaged over the three experiments. The percentage of each cell type was calculated based on square microns. Masses of the individual cell types were determined by multiplying the percentage of each cell type by the total endocrine mass. For assessment of TUNEL-positive acinar cells, TUNEL-positive cells were counted at 240· and entire pancreas sections were imaged at 60·. Area of acinar tissue was quantified using IPLab.
For assessing whether Ngn3-expressing cells were present in postnatal mice, we both stained pancreata for Ngn3 expression and collected pancreata from P7 Jagged1 loxP/loxP ; Foxa3-Cre + and Jagged1 loxP/+ ;Foxa3-Cre À pups that were determined by PCR to contain a Ngn3-eGFP allele. These pancreata were dissected and fixed for 2 h in 4% PFA, rinsed in PBS, and then embedded in agarose before sectioning with a vibratome at 100 lm. These sections were examined using confocal microscopy (Leica, Longueuil, Canada). For quantification of embryonic endocrine precursors, sections were stained with Ngn3 and counterstained with DAPI. Ngn3-positive nuclei were hand-counted at 240·. Entire sections were imaged at 120· and DAPI-stained nuclei were counted using the ''auto-segment'' function of IPLab. For quantification of embryonic glucagon-and insulin-positive cells, images of every glucagon-or insulin-positive cell were taken at 120· or 200· and counted by hand. Then entire sections were imaged at 40· or 24· and the auto-segmentation function of IPLab was used to quantify area in square microns.
WCE from tissue for immunoblot were collected as described (Lee et al., 2002b) and from cell culture with 250 ll RIPA buffer which was then incubated on ice for 15 min before sonication and centrifugation. 75-80 lg WCE were loaded on an 8% SDS-PAGE gel or 4-12% Bis-Tris gel (Invitrogen, Carlsbad, CA, USA) and transferred to a membrane before being probed with primary and secondary antibodies and then developed with the Amersham ECL-Plus kit (Amersham, Piscataway, NJ, USA).
4.4.
Collection of Ngn3-eGFP-positive and -negative sorted cells
Collection of Ngn3-eGFP-positive cells, RNA extraction, and method of normalization for qRT-PCR has been reported previously (White et al., 2008) .
Quantitative reverse transcriptase PCR (qRT-PCR)
RNA was isolated and reverse-transcribed as previously described (Gupta et al., 2005) . PCR reaction mixes were assembled and reactions were performed on an Mx3000
TM or Mx4000 TM Multiplex Quantitative PCR System (Stratagene). For comparison of Notch ligand RNA levels, primers were designed within one exon within the last 700 bp of mRNA. The primers were tested on a dilution series of ES cell DNA. Unless otherwise indicated, TBP was used as the housekeeping gene for all qRT-PCR experiments. Primer sequences are listed in Supplementary Table 1.
Statistics
Data were analyzed using Student's t-test with equal distribution and either one or two-tailed analysis, as appropriate.
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